MedPath

Clinical Validation of DACP Digital Design

Not Applicable
Completed
Conditions
Refractive Errors
Interventions
Device: Nelfilcon A digital contact lenses
Device: Nelfilcon A contact lenses
Registration Number
NCT03567005
Lead Sponsor
Alcon Research
Brief Summary

The purpose of this study is to evaluate the visual performance of DAILIES® AquaComfort Plus® (DACP) Digital lenses by assessing distance visual acuity (VA) as compared to DACP sphere contact lenses after one week of wear.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Willing and able to sign an IRB/IEC approved Informed Consent form;
  • Current wearer of DACP spherical contact lenses (at least 2 months in current correction), with a minimum wearing time of 5 days per week and 8 hours per day;
  • Experiencing symptoms of eye strain from using technology;
  • Willing to wear study lenses each day;
  • Possess spectacles that provide a corrected visual acuity of 20/40 or better in both eyes (OU) and be willing to wear them (as needed);
  • Willing to NOT use rewetting/lubricating drops at any time during the study;
  • Currently using digital devices (computer, tablet, and/or smart phone) for a minimum of 5 days per week and 4 hours per day;
  • Willing to NOT use any near aid (e.g. reading glasses) at any time during the study.
Exclusion Criteria
  • Conditions, use of medications, injury, or surgery, as specified in the protocol;
  • Wearing habitual contact lenses in an extended wear modality (routinely sleeping in lenses for at least 1 night per week) over the last 3 months prior to enrollment;
  • Monocular (only one eye with functional vision);
  • Pregnant.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
DACP then DACP DigitalNelfilcon A digital contact lensesNelfilcon A contact lenses worn first, followed by nelfilcon A digital contact lenses. Each product worn bilaterally for 7 days in a daily disposable modality.
DACP Digital then DACPNelfilcon A digital contact lensesNelfilcon A digital contact lenses worn first, followed by nelfilcon A contact lenses. Each product worn bilaterally (in both eyes) for 7 days in a daily disposable modality.
DACP Digital then DACPNelfilcon A contact lensesNelfilcon A digital contact lenses worn first, followed by nelfilcon A contact lenses. Each product worn bilaterally (in both eyes) for 7 days in a daily disposable modality.
DACP then DACP DigitalNelfilcon A contact lensesNelfilcon A contact lenses worn first, followed by nelfilcon A digital contact lenses. Each product worn bilaterally for 7 days in a daily disposable modality.
Primary Outcome Measures
NameTimeMethod
Distance Visual Acuity (VA) (logMAR, OU)Day 7, each product

VA was tested under photopic (well-lit) conditions using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart positioned 6 meters from the subject. VA was collected bilaterally (OU) and measured in logMAR (logarithm of the minimum angle of resolution), with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on the ETDRS chart. A lower numeric value represents better visual acuity.

Secondary Outcome Measures
NameTimeMethod
Overall VisionDay 7, each product

Subjective rating of overall vision on a scale of 1 (Poor) to 10 (Excellent). Both eyes contributed to the analysis.

Trial Locations

Locations (1)

Alcon Investigative Site

🇺🇸

Memphis, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath